<DOC>
	<DOCNO>NCT01157715</DOCNO>
	<brief_summary>This study design access safety efficacy multiple injection KH902 variable dosing regimens patient CNV due neovascular AMD .</brief_summary>
	<brief_title>A Randomized , Double-masked , Multicenter , Controlled Study Intravitreal KH902 Patients With Neovascular AMD</brief_title>
	<detailed_description>AMD lead cause severe vision loss people age 65 United States western country . A quantity document indicate neovascularization promote VEGF main cause visual acuity decline . Patients starve new drug notably improve VA less administration frequency lower treatment cost . The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein ( KH902 ) gene fusion protein . The pre-clinical research phase I study show KH902 effective safe inhibiting growth , migration , pullulation vascular endothelial cell neovascularization induce VEGF . This study design confirm efficacy safety multiple injection KH902 variable dose regimen patient CNV due neovascular AMD . Based characteristic KH902 result KH902 Phase I study well reference clinical trial similar drug , determine KH902 administrate 0.5mg/eye/time 2.0mg/eye/time .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Inclusion criterion : Signed ICF ; Age ≥ 50 year either gender ; Active primary recurrent lesion subfoveal juxtafoveal CNV secondary neovascular AMD study eye ; Lesion size ≤ 12 disc area either eye ; BCVA study eye 73 24 letter , inclusively , BCVA fellow eye ≥ 19 letter ; Clear ocular medium adequate pupil dilation . If eye eligible , one select . Exclusion criterion : History vitreous hemorrhage , retinal detachment macular hole , presence retinal pigment epithelial tear , retinal macular traction macular epiretinal membrane study eye ; Subfoveal scar atrophy study eye ; Subretinal hemorrhage study eye ; Uncontrolled glaucoma either eye ; Active inflammation infection either eye ; Previous drug treatment , either antiVEGF drug steroid derivative , and/or , previous ophthalmologic operation laser therapy study eye ; History surgery within one month precede enrollment ; Any uncontrolled clinical disorder ; Patients childbearing potential adopt adequate contraception method ; Pregnant nursing woman ; Patients need exclude opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>KH902</keyword>
	<keyword>age-related macular degeneration ( AMD )</keyword>
	<keyword>choroidal neovascularization ( CNV )</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>best correct visual acuity ( BCVA )</keyword>
	<keyword>central retinal thickness</keyword>
</DOC>